PMC

Attack-free survival among patients with acquired angioedema with anti-C1INH antibodies and patients with acquired angioedema without anti-C1INH antibodies. Kaplan–Meier analysis of survival without attacks among 41 patients with acquired angioedema without anti-C1INH antibodies (white circle line) and 40 patients with acquired angioedema with anti-C1INH antibodies (black circle line), for whom data were available; log-rank test P = 0.045. C1INH = C1-inhibitor.

Cumulative record of localization of angioedema attacks over time among patients with AAE—general cohort and subgroups according to associated disease. A patient frequently has different localizations along time. χ² test was applied for comparison between lymphoid malignancy, monoclonal gammopathy, and no associated disease subgroups. AAE = acquired angioedema.

Rituximab administration and response of AAE. A response was defined as no attacks or a decrease of attack frequency of >50% during the 6 months following administration or introduction of rituximab. AAE = acquired angioedema, anti-C1INH = anti-C1INH antibody, C1INH = C1-inhibitor, MGUS = monoclonal gammopathy of undetermined significance, n = number of patients, RA = rheumatoid arthritis.